Safety and therapeutic effect of mesenchymal stem cell infusion on moderate to severe ulcerative colitis

Abstract

One of the primary targets of the clinical treatment of ulcerative colitis (UC) is to repair the damaged colonic mucosa. Mesenchymal stem cells (MSCs) have therapeutic potential in regenerative medicine due to their differentiation capacity and their secretion of numerous bioactive molecules. The present study describes a clinical trial (trial registration no. NCT01221428) investigating the safety and therapeutic effect of MSCs derived from human umbilical cord on moderate to severe UC. Thirty-four patients with UC were included in group I and treated with MSC infusion in addition to the base treatment, and thirty-six patients were in group II and treated with normal saline in addition to the base treatment. One month after therapy, 30/36 patients in group I showed good response, and diffuse and deep ulcer formation and severe inflammatory mucosa were improved markedly. During the follow up, the median Mayo score and histology score in group I were decreased while IBDQ scores were significantly improved compared with before treatment and group II (P<0.05). Compared with group II, there were no evident adverse reactions after MSC infusion in any of the patients in group I, and no chronic side effects or lingering effects appeared during the follow-up period. In conclusion, MSC infusion might be a useful and safe therapy for treating UC.

Introduction

Ulcerative colitis (UC) is a chronic inflammatory bowel disease affecting the mucosa and submucosa of the rectum, which may extend to the entire colon, and is characterized by a relapsing and remitting course (1). The symptoms of UC commonly include bloody diarrhea, rectal bleeding or rectal urgency. The severity of these symptoms is typically related to the extent of mucosal inflammation and can be observed by colonoscopy (2,3). The induction of remission and mucosal healing are the goals of therapy. Aminosalicylates, azathioprine, 6-mercaptopurine and infliximab may be used for maintenance, however, the above treatments do not adequately work in all patients or are not well tolerated (4,5). There remains an urgent need for novel therapeutic options to cure UC.

Mesenchymal stromal cells (MSCs) can be easily isolated and amplified from umbilical cord and other tissues. The characteristics of MSCs result in extensive use in numerous diseases, including tissue degeneration and refractory chronic inflammatory diseases (6). In UC, the inflammatory response is mediated by cytokines similar to the Th2 response and different immunocytes (7). The involvement of T-cells, natural killer (NK) cells and dendritic cells in UC pathophysiology has been confirmed in a large recent genome-wide association study (8). Recent data have indicated that MSCs can restore tissues by their immunomodulatory function, differentiation and paracrine effects. MSCs can modulate allogeneic immune cell responses by affecting dendritic cells, T-lymphocytes and NK cells (9). In addition, MSCs appear to regulate the immune reaction in inflamed tissues by affecting the formation and secretion of pro-inflammatory cytokines and chemokines, such as prostaglandin E2 and interleukin (IL)-6 (10). MSCs may induce a cytokine profile shift in the T helper (Th) 1/Th2 balance toward the anti-inflammatory phenotype Th2, which is accompanied by an increase of T regulatory lymphocytes and IL-10 (11,12).

Regarding the treatment of UC, it can be suggested that MSCs are effective by their immune modulatory properties coupled with a tissue repair capacity. Based on this consideration and current findings, a clinical trial (trial registration no. NCT01221428) was performed to investigate the safety and therapeutic effect of MSCs derived from human umbilical cord on moderate to severe UC.

Materials and methods

Study design

The present trial was a phase I/II, 24 month, randomized controlled study conducted in patients with moderate to severe UC. The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethical Committee of the Affiliated Hospital of Qingdao University (Qingdao, China). Each patient provided written informed consent prior to entering the study. During the whole study, the investigators remained blind to the treatment administered.

Patients

Between September 2011 and December 2012, all patients were selected from The Affiliated Hospital of Qingdao University for the treatment of UC. UC was diagnosed according to current established clinical, endoscopic, radiologic and histologic guidelines (13). The extent of UC was evaluated based on the Mayo score classification (14,15). Eligibility criteria for study entry included patients ≥18 years of age, diagnosed with active UC with a Mayo score at baseline (range between 8 and 10). Exclusion criteria included infectious complications, toxic megacolon, previous colorectal surgery, history of colorectal dysplasia or any malignancy, pregnancy and any psychological illness.

Treatment

All patients were on stable doses of aminosalicylates for ≥4 weeks prior to enrollment and all patients continued their individual regimens throughout the trial. Patients in group I were treated with MSC infusions twice besides the base treatment, one via injection into the veins in the back of the hand, and the other injected into the superior mesenteric artery by interventional catheterization, with a 7 day interval. Patients in group II were treated the same but with normal saline, which had the same volume and appearance as the MSC solution. The volumes of the parenteral solution of MSCs and normal saline for intravenous injection in the two groups were 50 ml and the average cell number was 3.8±1.6×10⁷ (0.5×10⁶ cells/kg; range, 2.3–4.7×10⁷ cells), and the volumes of the parenteral solution of MSCs and normal saline for mesenteric artery injection by interventional catheterization in the two groups were 10 ml and the cell number was 1.5×10⁷. To undergo MSC infusion, all patients were admitted to The Affiliated Hospital of Qingdao University. During the follow-up, the dosage of aminosalicylates administered were adjusted according to the patients condition.

MSCs were provided by the Human Umbilical Cord Mesenchymal Stem Cell Bank (Qingdao, China)

MSCs were cultured and expanded in a laminar flow laboratory (designed according to Good Medical Practice) for four passages to prepare stable final cell products that qualify for aerobe, mycoplasma, hepatitis B virus, hepatitis C virus, human immunodeficiency virus, Epstein-Barr virus, cytomegalovirus, syphilis and endotoxin testing. Cells were stained with CD-PE and CD-FITC (from the Human MSC Analysis kit; cat. no. 562245; BD Biosciences, Franklin Lakes, NJ, USA) and then analyzed by flow cytometry with a FACSCalibur flow cytometer (BD Biosciences). These cells highly expressed cluster of differentiation (CD) 90 (89.37%), CD105 (82.26%), CD73 (90.63%), and CD146 (65%) but not CD34 (0.23%), CD45 (0.02%) and Human Leukocyte Antigen-D Related (0.03%) (Human MSC Analysis kit). The chromosomal karyotype of UC-MSC was determined as normal using a Metascan Karyotyping System (Imstar, Paris, France).

Clinical assessment and follow-up

The final evaluation prior to the first infusion of MSC was used as baseline for all analyses. Laboratory assessments of C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), blood counts, liver enzymes, total protein, albumin, total cholesterol, triacylglycerol, serum urea nitrogen, creatinine and electrolytes were performed in the Clinical Laboratory of The Affiliated Hospital of Qingdao University. All samples were handled by the Clinical Laboratory of The Affiliated Hospital of Qingdao University. Full Mayo scores and Inflammatory Bowel Disease Questionnaire (IBDQ) scores (16,17) were determined every 3 months in the first year after therapy, and then every 6 months during the second year of follow-up. The Mayo subscores for stool frequency and rectal bleeding were calculated based on entries from patient diaries using the worst diary entry from the 3 days before each study visit for each subscore. In all patients who had undergone follow-up endoscopy, it was assessed whether mucosal healing was achieved or not. Clinical response was defined as a decrease from baseline in the total Mayo score of ≥3 points and ≥30%, with an accompanying decrease in the subscore for rectal bleeding of at least 1 point or an absolute subscore for rectal bleeding of 0 or 1. Clinical remission was defined as a total Mayo score of ≤2 points, with no individual subscore exceeding 1 point. Mucosal healing was defined as an absolute subscore for endoscopy of 0 or 1. Tissue samples of colon were fixed in 4% formalin solution overnight and embedded in paraffin by the conventional method, then cut into 4 µm thick sections. The sections were stained with hematoxylin and eosin for gross histological examination using a fluorescence microscope.

Study objectives

The primary study endpoint was safety and a clinical response documented by full Mayo scores and IBDQ scores at 3 months following treatment completion, and the secondary endpoints were safety and improvements of Mayo scores and IBDQ scores at 24 months.

Safety assessments

Patients were monitored continuously for adverse events, including evaluations every 2 weeks during the follow-up period. Other safety parameters (vital signs and clinical laboratory parameters) were ascertained monthly.

Data collection

A data collection form was developed according to the objectives of the present study. Training of researchers and research assistants was performed during a pilot data collection period and the case record form was standardized. Site visits by internal and external auditors were performed regularly to assure quality of the data and the clinical trial process.

Statistical analysis

All statistic analyses were performed using SPSS version 15.0 software (SPSS, Inc., Chicago, IL, USA). Data are presented as the mean ± standard deviation. Differences between the means of the baseline values of group I and group II were analyzed using Students t–test. Comparisons between time-dependent changes at the time of baseline and different time points following treatment were performed using repeated measure analysis of variance and post hoc analysis with the Bonferroni correction. P<0.05 was considered to indicate a statistically significant difference.

Results

Patient characteristics

A total of 80 patients with UC were initially enrolled in the study (Fig. 1) and randomly divided into groups I and II. Four patients in group II and six patients in group I withdrew from the study following therapy because of intolerance of the colonoscopy examination or lack of time to take part in the study. In total, 70 patients completed the entire study and their data were analyzed. Overall, there were 43 men and 27 women, with mean age of 42.7±9.6 years (range, 18–52 years). The baseline characteristics of all patients are presented in Table I. There were no significant differences in clinical findings, laboratory examinations, Mayo scores or IBDQ scores between the two groups prior to the trial. A cancer screening test confirmed no cancer in all patients.

Figure 1.

Procedure of the trial. UC, ulcerative colitis; MSC, mesenchymal stem cell.

Table I.

Baseline patient characteristics.

Characteristic	Group I (n=34)	Group II (n=36)
Gender, male/female	21/13	22/14
Median age, year	42.9±23.1	43.7±28.7
Duration of disease, year	5.6±4.2	6.1±4.9
Extent of disease
Total colitis (%)	24 (70.6)	24 (66.7)
Left-sided colitis (%)	10 (29.4)	12 (33.3)
Mayo score at baseline	8.9±3.2	8.5±3.8
IBDQ at baseline	178.9±26.7	183.1±32.9
CRP, mg/l	35.96±15.75	37.58±19.03
ESR, mm/h	73±22.1	69±18.2

Values are presented as the number of patients or mean ± standard deviation. IBDQ, inflammatory bowel disease questionnaire; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate.

Safety evaluation

No clinical symptoms and no significant changes in vital signs were observed during and after cell therapy. Compared with group II, there were no evident adverse reactions following MSC infusion in any of the patients in group I, and no chronic side effects or lingering effects appeared during the follow-up period.

Efficacy

One month after therapy, 30/36 patients in group I showed good response, such as remission of stomachache, diarrhea and mucous bloody stool. All eligible patients underwent endoscopy at baseline and every follow-up point after therapy. As shown in Fig. 2, diffuse and deep ulcer formation and severe inflammatory mucosa were observed prior to therapy, but the findings were greatly improved in group I following therapy.

Figure 2.

Endoscopic findings of patients in group I before and after therapy.

Change in Mayo scores

Three months after therapy, the ratio of clinical responses (≥3 point decrease in the Mayo score) or remission (Mayo score 0 or 1) was significantly higher in group I compared with group II (85.3 vs. 15.7%; P=0.007; Fig. 3A). The median Mayo score was improved in 27 patients in group I at the third month after cell therapy and reached the lowest level at six months, then sustained or showed a little fluctuation during the entire follow-up period. In group II, the median Mayo score of all patients fluctuated during the entire follow-up period (Fig. 3B).

Figure 3.

Ratio of clinical response and change of Mayo scores over time. (A) The ratio of clinical response (>3 points decrease in Mayo score) in groups I (n=34) and II (n=36). *P=0.007 vs. group II. (B) The change of Mayo scores in groups I and II over time. *P<0.05 vs. group II. Mon, months.

Change in histological assessment scores

Histology scores from the colonic biopsies are presented in Fig. 4. The median histology score in group I decreased following cell therapy. Histological findings observed at baseline, including abruption of the surface layer, goblet cell depletion, crypt abscesses, gland collapse and inflammatory cell infiltration, improved following therapy. The median histology score in group I was significantly lower compared with that in group II (P<0.05; Fig. 4).

Figure 4.

Pathological findings and change in histological scores over time. (A) The change of pathological findings in patients of group I before and after therapy; magnification, ×10. (B) The change of histological scores in the two groups over time. *P<0.05 vs. group II. Mon, months.

Change in IBDQ scores

Inflammatory Bowel Disease Questionnaire (IBDQ) scores were analyzed to evaluate any therapy-induced changes in health-related quality of life. Fig. 5 shows changes in total IBDQ scores. The IBDQ scores in group I were significantly improved compared with baseline (128.6 vs. 181.9; P=0.002) at the third month of the trial, and were higher than group II from the sixth month of the trial. Although IBDQ scores steadily increased in group II throughout the trial, the change in scores failed to reach statistical significance by the end of the trial (P>0.05).

Figure 5.

Change of IBDQ scores over time in groups I and II. *P<0.05 vs. group II. IBDQ, Inflammatory Bowel Disease Questionnaire score; mon, months.

Change in cytokine levels and blood test

The mean plasma cytokine levels, including TNF-α, IL-6 and IFN-γ, were not significantly different between the two groups at baseline and during the follow-up period.

The changes in results of blood test between the two groups was analyzed. In group I, CRP and ESR significantly decreased at the third month (0.62 to 0.18 mg/l, P=0.03; 76 to 23 mm/h, P=0.02) compared with the baseline. There was no significantly difference between two groups. Data are presented in Fig. 6. There were no other significant changes and no adverse events related to blood count, hemoglobin and hematocrit, liver enzymes, total protein, albumin, total cholesterol, triacylglycerol, serum urea nitrogen, creatinine and electrolytes in group I compared with group II (data not presented).

Figure 6.

Change of (A) CRP and (B) ESR in groups I and II. Three months after therapy, the levels of CRP and ESR in the two groups significantly decreased at the third month compared with the baseline measurement; *P<0.05 vs. group I baseline; *P<0.05 vs. group II baseline. There was no significant difference between the two groups after therapy.

Discussion

One of the main targets of the clinical treatments for UC is to repair the damaged colonic mucosa. MSCs have great therapeutic potential in regenerative medicine due to their differentiation capacity and their secretion of numerous bioactive molecules (18). There are a number of studies focused on the attractive regenerative properties of MSCs, and evidence indicating that MSCs can promote regeneration of injured tissue (19–22). MSCs have low immunogenicity and display immunosuppressive proprieties (23), and can trigger the release of anti-inflammatory cytokines (24). Their capacity to suppress T cell activities and induce apoptosis provides a rationale for applying these cells in UC therapy (25,26).

In the present clinical trial, the safety and therapeutic effect of MSCs derived from human umbilical cord were investigated on patients with moderate to severe UC and followed up for two years. The results showed that all evaluations, including endoscopic findings, pathological findings, Mayo scores and IBDQ scores, were markedly improved in group I following MSCs infusion compared with baseline and group II. These results indicate that MSC infusion is a safe and effective therapy for UC.

Mechanisms directing in vivo homing and engraftment of MSCs are unclear and depend on complex interactions between numerous signaling events. Several studies have demonstrated the ability of MSCs to preferentially migrate to sites of injury when infused in animal models (27–29). After receiving appropriate signals during tissue inflammation, MSCs could migrate to the lesions of the colon where they assisted in recovery, displaying high therapeutic potential with regards to tissue repair and/or the control of local inflammation (30). The expression of growth factors, cytokines and extracellular matrix receptors by MSCs may drive this process (31,32). In the present study, the endoscopic findings, pathological findings and Mayo scores of patients in group I were markedly improved compared with group II, indicating that MSCs serve a role at the local sites.

MSCs can reduce colonic inflammation by downregulating the production of inflammatory mediators by mucosal immune cells, and by increasing the levels of the anti-inflammatory cytokines (33). In UC, the immunologic response is reflected by the imbalance in Th1 and Th2 cells, and thus the cytokine production at different stages of disease (34). Intravenous treatment with MSCs could increase the levels of the anti-inflammatory cytokines IL-10 and IL-4, and decrease the levels of the pro-inflammatory cytokine IL-6 (35,36). Chatterjee et al (37) demonstrated that high levels of IFN-γ produced by T cells in contact with MSCs resulted in the activation of the immunosuppressive effect of MSCs. Crucitti et al (38) assessed the therapeutic effect of MSCs by measuring inflammatory cytokines such as TNF-α, IFN-γ, IL-6 and IL-1β, and chemokines, such as macrophage inhibitory protein II, which were significantly decreased in treated mice. Hengartner et al (39) assessed the MSC therapeutic effect by measuring the RNA expression of inflammatory mediators such as TNF-α, IL-1β, cyclo-oxygenase 2, basic fibroblast growth factor, hepatocyte growth factor and vascular endothelial growth factor, all of which significantly decreased in MSC-treated mice. In a study by Forte et al (40), human umbilical cord MSCs were used to treat acute trinitrobenzene sulfonic acid-induced UC. In another study, the inflammatory markers such as IL-17, IL-23, IFN-γ and IL-6 were measured to assess the therapeutic efficacy of human umbilical cord MSCs and were shown to be significantly decreased in the treated mice (41). In the present study, during the follow-up, the levels of cytokines in group I, including TNF-α, IL-6 and IFN-γ, were not significantly changed compared with group II. This may be due to the complexity of the body; however, the exact mechanisms need to be clarified.

Although the exact mechanisms underlying MSC-mediated suppression of lymphocyte proliferation remain essentially unknown, it is possible that MSCs can accelerate apoptosis of active inflammatory cells. Akiyama et al (42) showed that the systemic infusion of MSC-induced T cell apoptosis via the Fas ligand-dependent Fas pathway, reducing symptoms of dextran sulfate sodium-induced colitis. MSCs modulate their micro-environment by exerting powerful immunosuppressive effects (43,44). These cells inhibit cell proliferation and the cytotoxic potential of NK cells and CD8⁺ T cells (45). Furthermore, MSCs impair the maturation, cytokine production and T cell stimulatory capacity of dendritic cells. In addition, MSCs suppress the proliferation and antibody production of B cells, inhibit the proliferation and cytokine secretion of CD4⁺ T lymphocyte subsets, and promote the expansion of regulatory T cell populations (46).

In the present clinical trial, there were no evident adverse reactions following MSC infusion in any of the patients who completed the study protocol, and no chronic side effects or lingering effects appeared during the follow-up period. In addition, the therapeutic effect of MSC infusion was sustained during the entire follow-up period. However, the chronic effect of MSC infusion in treating UC need to explore by an extended follow-up period. In conclusion, MSC infusion may become a useful and safe therapy for patients with UC.